Skip to main content
Premium Trial:

Request an Annual Quote

Risky Science and Grants

John Niederhuber, the director of the National Cancer Institute, responds to the recent criticism on how cancer-related grants are doled out — the New York Times' Gina Kolata said that it leads to researchers avoiding risky projects that she thinks may have better payoffs. Niederhuber says that Kolata's criticisms are nothing new and that despite its flaws, the peer-review system "remains the envy of the world—and one of the most duplicated." He also says that while scientists "put their best science forward in their R01 grant proposals," there are other ways to fund riskier science. "In my interview for the Times story, I suggested to Ms. Kolata that the very nature of cancer science is beginning to undergo fundamental change and that not all scientific risk takes place in the realm of the classic R01 or similar grants," he adds.

Michael White at Adaptive Complexity says that Niederhuber's response actually helps support Kolata's thesis. "Note that he equates the 'best science' that goes into R01s with non-risky science — he essentially admits that he believes risky science is not the best science," he writes, adding that he did consider the Times piece "too dismissive of the progress that's been made in the understanding and treatment of cancer."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.